Lupin Ltd gets two observations from USFDA for Ankleshwar facility

The U.S. FDA has concluded an inspection at Lupin Ltd's manufacturing facility at Ankleshwar, India. The Inspection was conducted from March 02, 2026 to March 07, 2026 and closed with the issuance of a Form-483 with two observations.

The company will address the observations and respond to the U.S. FDA within the stipulated timeframe. The company is committed to be compliant with CGMP standards across all our facilities.

Shares of Lupin Limited was last trading in BSE at Rs. 2344.45 as compared to the previous close of Rs. 2332.40. The total number of shares traded during the day was 18759 in over 3104 trades.

The stock hit an intraday high of Rs. 2368.00 and intraday low of 2325.00. The net turnover during the day was Rs. 44033927.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 Pharmaceuticals Ankleshwar Facility USFDA Form483